+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Pemetrexed Diacid Market Size by Consumption Type, by Cancer Type, by Therapeutic Modality, by Geographic Scope And Forecast

  • PDF Icon


  • 98 Pages
  • April 2020
  • Region: Global
  • Verified Market Research
  • ID: 5301555
Pemetrexed Diacid Market Overview

Pemetrexed Diacid Market was valued at USD 4.35 billion in 2019 and is projected to reach USD 6.84 billion by 2027, growing at a CAGR of 6.7% from 2020 to 2027.

Factors influencing the market

Factors that are driving the growth of the market include the rising Instances of lung cancer. Lung cancer, also known as lung carcinoma, is a malignant lung tumor characterized by uncontrolled cell growth in tissues of the lung. This growth can spread beyond the lung by the process of metastasis into nearby tissue or other parts of the body. Most cancers that start in the lung, known as primary lung cancers, are carcinomas. The two main types are small-cell lung carcinoma (SCLC) and non-small-cell lung carcinoma (NSCLC). Pemetrexed Diacid is majorly used to treat non-small lung carcinoma.

Global Pemetrexed Diacid Market: Segmentation Analysis

The Global Pemetrexed Diacid Market is segmented based on Consumption Type, Cancer Type, By Therapeutic Modality and Geography.

Global Pemetrexed Diacid Market Segment Analysis

The Global Pemetrexed Diacid market can be segmented into Consumption Type, Cancer Type, Therapeutic Modality.

Pemetrexed Diacid Market Competitive Landscape:

Some of the major players involved in the Global Pemetrexed Diacid Market are Eli Lilly and Company, Fresenius KABI, Teva Pharmaceutical Industries Ltd., Dr Reddy’s Laboratories, Abbott Laboratories, Cadila Healthcare Ltd, Accord Healthcare Inc., QILU Pharma Co Ltd., Accure Labs Pvt. Ltd, Pfizer Inc.

Table of Contents

1 Introduction of Global Pemetrexed Diacid Market
1.1 Market Overview
1.2 Market Segmentation
1.3 Assumptions
2 Executive Summary
2.1 Overview of the Market
2.2 Global Pemetrexed Diacid Market, by Consumption Type (Usd Million)
2.3 Global Pemetrexed Diacid Market, by Cancer Type (Usd Million)
2.4 Global Pemetrexed Diacid Market Shares, by Therapeutic Modalities, 2016 (%)
2.5 Global Pemetrexed Acid Market, by Geography (Usd Million)
3 Research Methodology
3.1 Data Mining
3.2 Secondary Research
3.3 Primary Research
3.4 Subject Matter Expert Advice
3.5 Quality Check
3.6 Final Review
3.7 Validation
3.8 Primary Interviews
3.9 Research Scope and Assumptions
3.10 List of Data Sources
4 Global Pemetrexed Diacid Market Outlook
4.1 Market Dynamics
4.1.1 Market Drivers Rising Instances of Lung Cancer Increasing Consumption of Chemotherapy Drugs in Developing Countries
4.1.2 Market Restraints High Cost of Chemotherapy Drug Development Effects of Pemetrexed Diacid
4.1.3 Market Challenges Loss of Patent Exclusivities Giving Rise to Generics
4.2 Porter's Five Force Analysis
5 Global Pemetrexed Diacid Market, by Consumption Type
5.1 Overview
5.2 in Combination With Cisplatin/Carboplatin
5.3 Supplement
6 Global Pemetrexed Diacid Market, by Cancer Type
6.1 Overview
6.2 Lung Cancer
6.3 Liver Cancer
6.4 Colorectal Cancer
6.5 Stomach
6.6 Breast
6.7 Others
7 Global Pemetrexed Diacid Market, by Therapeutic Modality
7.1 Overview
7.2 Chemotherapy
7.3 Immunotherapy
7.4 Other
8 Global Pemetrexed Diacid Market, by Geography
8.1 Overview
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.2.3 Mexico
8.3 Europe
8.3.1 Germany
8.3.2 Uk.
8.3.3 France
8.4 Asia-Pacific
8.4.1 China
8.4.2 Japan
8.4.3 India
8.5 Latin America
8.5.1 Brazil
8.6 Rest of the World
9 Competitive Landscape
10 Company Profiles
10.1 Eli Lilly and Company
10.1.1 Company Overview
10.1.2 Eli Lilly and Company: Key Facts
10.1.3 Financial Performance
10.1.4 Product Benchmarking
10.1.5 Eli Lilly and Company: SWOT Analysis
10.2 Fresenius Kabi
10.2.1 Company Overview
10.2.2 Fresenius Kabi: Key Facts
10.2.3 Financial Performance
10.2.4 Product Benchmarking
10.2.5 Fresenius Kabi: SWOT Analysis
10.3 Teva Pharmaceutical Industries Ltd
10.3.1 Company Overview
10.3.2 Teva Pharmaceutical Industries Ltd.: Key Facts
10.3.3 Financial Performance
10.3.4 Product Benchmarking
10.3.5 Teva Pharmaceutical Industries Ltd.: SWOT Analysis
10.4 Dr Reddy's Laboratories
10.4.1 Company Overview
10.4.2 Dr Reddy's Laboratories: Key Facts
10.4.3 Financial Performance
10.4.4 Product Benchmarking
10.4.5 Dr. Reddy's Laboratories: SWOT Analysis
10.5 Abbott Laboratories
10.5.1 Company Overview
10.5.2 Abbott Laboratories: Key Facts
10.5.3 Financial Performance
10.5.4 Product Benchmarking
10.5.5 Abbott Laboratories: SWOT Analysis
10.6 Cadila Healthcare Ltd.
10.6.1 Company Overview
10.6.2 Cadila Healthcare: Key Facts
10.6.3 Financial Performance
10.6.4 Product Benchmarking
10.7 Accord Healthcare Inc.
10.7.1 Company Overview
10.7.2 Accord Healthcare Inc.: Key Facts
10.7.3 Financial Performance (Intas Pharmaceuticals Ltd.)
10.7.4 Product Benchmarking
10.8 Qilu Pharma Co Ltd
10.8.1 Company Overview
10.8.2 Qilu Pharma Co Ltd: Key Facts
10.8.3 Product Benchmarking
10.9 Accure Labs Pvt. Ltd
10.9.1 Company Overview
10.9.2 Accure Labs Pvt. Ltd: Key Facts
10.9.3 Product Benchmarking
10.10 Pfizer Inc.
10.10.1 Company Overview
10.10.2 Pfiser Inc :Key Facts
10.10.3 Financial Performance
10.10.4 Product Benchmarking

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Eli Lilly and Company
  • Fresenius KABI
  • Teva Pharmaceutical Industries Ltd.
  • Dr Reddy’s Laboratories
  • Abbott Laboratories
  • Cadila Healthcare Ltd
  • Accord Healthcare Inc.
  • QILU Pharma Co Ltd.
  • Accure Labs Pvt. Ltd
  • Pfizer Inc